DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Lupus
  4. Research Highlights/News
  5. 2020 Lupus Research Program

Lupus

NEWS RELEASE

Released: April 15, 2020

Defense Health Program
Department of Defense Lupus Research Program
Anticipated Funding Opportunities for Fiscal Year 2020 (FY20)

The FY20 Defense Appropriations Act provides funding to the Department of Defense Lupus Research Program (LRP) to support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

The LRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunity. This pre-announcement should not be construed as an obligation by the Government. The FY20 LRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released. 

Applications submitted to the FY20 LRP Idea Award and/or Impact Award must address one or more of the following Focus Areas: 

  • Understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies
  • Understanding lupus disease heterogeneity including, but not limited to, strategies and technologies to subtype patients and understanding lupus disease mechanisms
  • Improving quality of life for individuals living with lupus including, but not limited to, access to healthcare resources, outcome research, symptom control, comparative effectiveness research, and issues and challenges that when addressed make day-to-day living with lupus easier and life more fulfilling
  • Understanding how the underlying genetic components and gene-environment interactions of lupus relate to clinical disease characteristics using functional genomic studies
  • Determining the pathobiology of lupus disease in target human tissues including, but not limited to, imagining studies, genomics of lupus in particular tissues, and metabolomics

Applications submitted to the FY20 LRP Transformative Vision Award must address the following Focus Area: 

  • Improving quality of life for individuals living with lupus including, but not limited to, access to healthcare resources, outcome research, symptom control, comparative effectiveness research, and issues and challenges that when addressed make day-to-day living with lupus easier and life more fulfilling

Award Mechanism Eligibility Key Mechanism Elements Funding
Idea Award Investigators at or above the level of postdoctoral fellow (or equivalent).
  • Supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement.
  • Emphasis is on innovation.
  • Clinical trials are not allowed.
  • Preliminary data are not required.
  • Maximum funding of $300,000 for total costs (direct plus indirect costs).
  • Maximum period of performance is 2 years.
Impact Award Investigators at or above Assistant Professor (or equivalent).
  • Supports high-risk/high-reward research, which if successfully addressed, has the potential to make a major impact in lupus research.
  • Emphasis is on impact.
  • Clinical trials are not allowed.
  • Preliminary data are encouraged but not required.
  • Maximum funding of $750,000 for total costs (direct plus indirect costs).
  • Maximum period of performance is 4 years.
Transformative Vision Award Investigators at or above Assistant Professor (or equivalent).
  • Supports research that will have near-term impacts on the health-related quality of life of patients of all ages and those with disproportionate health burdens.
  • Emphasis is on near-term impact to quality of life.
  • Clinical trials are allowed.
  • Animal studies are not allowed.
  • Preliminary data are required.
  • Maximum funding of $2.5 million for total costs (direct plus indirect costs).
  • Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (https://CDMRP.HEALTH.MIL).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Tuesday, November 12, 2024